Compounds > 6-(1-(4-fluorophenyl)methyl-1h-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acid ethyl ester
Page last updated: 2024-11-11

6-(1-(4-fluorophenyl)methyl-1h-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acid ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6479506
CHEMBL ID45578
MeSH IDM0484384

Synonyms (9)

Synonym
ethyl (e)-6-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxo-hex-5-enoate
5-hexenoic acid, 6-[1-[(4-fluorophenyl)methyl]-1h-pyrrol-2-yl]-2,4-dioxo-, ethyl ester, (5e)-
rds 1643
(e)-6-[1-(4-fluoro-benzyl)-1h-pyrrol-2-yl]-2,4-dioxo-hex-5-enoic acid ethyl ester
bdbm50142734
CHEMBL45578 ,
ethyl (e)-6-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxohex-5-enoate
ethyl (e)-6-(1-(4-fluorobenzyl)-1h-pyrrol-2-yl)-2,4-dioxohex-5-enoate
692756-12-0
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)10.18330.00011.076810.0000AID1053412; AID1198748; AID1198751; AID1198753; AID1565220; AID662969
Integrase Human immunodeficiency virus 1IC50 (µMol)93.33330.00051.544310.0000AID1053411; AID93678
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID104984Effective concentration required to reduce the exponential growth of MT-4/KB cells2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays.
AID1198753Inhibition of HIV1 reverse transcriptase Lys103Asn mutant-associated DNA polymerase-independent RNase H activity after 1 hr2015European journal of medicinal chemistry, Mar-26, Volume: 93(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID93678Inhibitory activity against HIV-1 integrase.2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays.
AID1198751Inhibition of HIV1 reverse transcriptase Tyr181Cys mutant-associated DNA polymerase-independent RNase H activity after 1 hr2015European journal of medicinal chemistry, Mar-26, Volume: 93(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID1198749Inhibition of HIV1 reverse transcriptase-associated RNA-dependent DNA polymerase activity after 30 mins2015European journal of medicinal chemistry, Mar-26, Volume: 93(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID1053412Inhibition of RNase H activity of recombinant HIV1 reverse transcriptase using poly(dC)-[3H]poly(rG) as substrate2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID662969Inhibition of HIV1 reverse transcriptase RNase H activity2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID232776Selectivity index was determined2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays.
AID1053411Inhibition of strand transfer activity of recombinant HIV1 integrase using 5'-end-labeled 21-mer double-stranded DNA as substrate after 60 mins by electrochemiluminescent plate-based assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID649482Antiviral activity against wild type HIV1 assessed as inhibition of viral replication2012European journal of medicinal chemistry, Apr, Volume: 50Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
AID1053406Selectivity index, ratio of CC50 for human HeLa cells expressing CD4 to EC50 for HIV1 3B2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID1198752Inhibition of HIV1 reverse transcriptase Tyr181Cys mutant-associated RNA-dependent DNA polymerase activity after 30 mins2015European journal of medicinal chemistry, Mar-26, Volume: 93(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID1198754Inhibition of HIV1 reverse transcriptase Lys103Asn mutant-associated RNA-dependent DNA polymerase activity after 30 mins2015European journal of medicinal chemistry, Mar-26, Volume: 93(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID1565220Inhibition of His6-tagged HIV-1 reverse transcriptase RNase H using 5'-GTTTTCTTTTCCCCCCTGAC-3'-Fluorescein-labeled RNA/5'-CAAAAGAAAAGGGGGGACUG-3'-Dabcyl-labeled DNA as susbtrate incubated for 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID1053408Antiviral activity against HIV1 3B/LAI infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect measured survival after 5 days by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID1198748Inhibition of HIV1 reverse transcriptase-associated DNA polymerase-independent RNase H activity after 1 hr2015European journal of medicinal chemistry, Mar-26, Volume: 93(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.
AID1053409Antiviral activity against HIV1 3B infected in human HeLa cells expressing CD4 assessed as inhibition of viral replication after 2 days by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID1053407Cytotoxicity against human HeLa cells expressing CD4 after 24 hrs by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID212877Cytotoxic concentration required to reduce the viability of mock-infected cells was determined by using MTT assay2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.4920acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
l 731988
L 731988: structure in first source		2.0210
3-hydroxyquinolin-2(1h)-one
3-hydroxyquinolin-2(1H)-one: structure in first source. dihydroxyquinoline : Any hydroxyquinoline in which the number of hydroxy substituents is specified as two.		2.0710hydroxyquinoline;
quinolone
2-pyridinecarboxaldehyde-1-oxide-3,4-dimethoxybenzene sulfonylhydrazone
2-pyridinecarboxaldehyde-1-oxide-3,4-dimethoxybenzene sulfonylhydrazone: structure given in first source		2.0710
raltegravir
[no description available]		2.53201,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone
2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone: structure in first source		2.0710
ConditionIndicatedRelationship StrengthStudiesTrials